Figure 1
NO synthesis in cultured VSMC treated with LPS (100 μg/mL), LPS+AG (30 mM), BGF (12 mM), or LPS + BGF (12mM), analyzed by the chemiluminescence method. Mean ± SEM (N=5 for all groups). *p < 0.05 vs. control (CTL); #P < 0.05 vs. LPS.
Figure 2
Dose-response of LPS (50, 100, or 200 μg/mL) on Cbfa1 or iNOS mRNA expression in VSMC. Representative RT-PCR amplification products using the primers for Cbfa1, iNOS, or β-actin.
Figure 3
Effects of LPS (100 µg/mL), LPS+AG (30 mM), LPS + BGF (12 mM), or BGF (12 mM) in Cbfa1 and iNOS expression. (A) Representative RT-PCR amplification products using the primers to Cbfa1, iNOS isoform, or β-actin. (B) Densitometric analysis of Cbfa1/β- actin or iNOS/β-actin. *p < 0.05 vs. CTL, #p < 0.05 vs. LPS.
Figure 4
Dose-response of AG (5, 10, 20, and 30 mM) on Cbfa-1 or iNOS mRNA expressions after 72 hours of treatment with LPS (100 µg/mL) in cultured VSMC. Representative RT-PCR amplification products using the primers for Cbfa1, iNOS isoform, or β-actin.
Figure 5
Cbfa1 immunocytochemistry. A- CTL, B- BGF (12 mM), C- LPS (100 µg/mL), D- LPS (100 µg/mL) + AG (30mM).